Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Sep 7;122(10):958-66.
doi: 10.1161/CIRCULATIONAHA.110.967406. Epub 2010 Aug 23.

Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis

Martin Reriani  1 , Eugenia Raichlin, Abhiram Prasad, Verghese Mathew, Geralyn M Pumper, Rebecca E Nelson, Ryan Lennon, Charanjit Rihal, Lilach O Lerman, Amir Lerman
Affiliations
Randomized Controlled Trial

Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis

Martin Reriani et al. Circulation. .

Abstract

Background: Endothelin (ET-1) is one of the most potent vasoconstrictors and plays a seminal role in the pathogenesis of atherosclerosis. The present study was designed to test the hypothesis that long-term treatment with an endothelin-A (ET(A)) receptor antagonist improves coronary endothelial function in patients with early coronary atherosclerosis.

Methods and results: Forty-seven patients with multiple cardiovascular risk factors, nonobstructive coronary artery disease, and coronary endothelial dysfunction were randomized in a double-blind manner to either the ET(A) receptor antagonist atrasentan (10 mg) or placebo for 6 months. Coronary endothelium-dependent vasodilation was examined by infusing acetylcholine (10(-6) to 10(-4) mol/L) in the left anterior descending coronary artery. N(G)-monomethyl-l-arginine was administered to a subgroup of patients. Endothelium-independent coronary flow reserve was examined by use of intracoronary adenosine and nitroglycerin. Baseline characteristics and incidence of adverse effects were similar between the 2 groups. There was a significant improvement in percent change of coronary blood flow in response to acetylcholine at 6 months from baseline in the atrasentan group compared with the placebo group (39.67%, 95% confidence interval 23.23% to 68.21%, versus -2.22%, 95% confidence interval -27.37% to 15.28%; P<0.001). No significant difference in the percent change of coronary artery diameter or change in coronary flow reserve was demonstrated. Coronary blood flow, coronary artery diameter, and the effect of N(G)-monomethyl-l-arginine were similar between the groups at baseline and at 6 months.

Conclusions: This study demonstrates that 6-month treatment with atrasentan improves coronary microvascular endothelial function and supports the role of the endogenous endothelin system in the regulation of endothelial function in early atherosclerosis in humans. Clinical Trial Registration Information- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00271492.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of random assignment to treatment, completion of the trial, and reasons for not completing it.
Figure 2
Figure 2
Difference in the mean percent change in Coronary Blood Flow and Coronary Artery Diameter in response to acetylcholine at six months from baseline for Atrasentan and placebo groups
See this image and copyright information in PMC

References

    1. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc. 1996;7:769–777. - PubMed
    1. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC., Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997–1001. - PubMed
    1. Lerman A, Holmes DR, Jr., Bell MR, Garratt KN, Nishimura RA, Burnett JC., Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92:2426–2431. - PubMed
    1. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993;191:1081–1088. - PubMed
    1. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995;92:357–363. - PubMed

Publication types

MeSH terms

Associated data